{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-020125","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.862336+00:00","generated_at":"2026-06-05T15:14:44.255324+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Revolution Medicines reports Q4 net loss $161.5M; cash $1.85B; pipeline on track for pivotal trials","bullets":["Q4 2023 net loss $161.5M vs $56.5M YoY; full year net loss $436.4M vs $248.7M YoY.","Revenue fell to $0.7M (Q4) and $11.6M (FY) due to Sanofi collaboration termination in 2023.","Cash, equivalents and securities $1.85B as of Dec 31, 2023, up from $644.9M a year ago (EQRx acquisition and equity offering).","Plans to start pivotal Phase 3 trials for RMC-6236 in 2L NSCLC and 2L PDAC in H2 2024.","2024 GAAP net loss guidance $480M-$520M; cash runway into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-020125","json":"https://secwatch.observer/filing/0000950170-24-020125.json","markdown":"https://secwatch.observer/filing/0000950170-24-020125.md","text":"https://secwatch.observer/filing/0000950170-24-020125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000095017024020125/0000950170-24-020125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000095017024020125/rvmd-20240226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T15:14:44.255324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07eb062283fcd5a5f4aeb1d49600260f4bc1b8d8","claim":"Revolution Medicines, Inc. reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017024020125/0000950170-24-020125-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}